Related Experiment Videos

[ACE inhibitors, beta blockers, AT-1 antagonists in heart failure. Right dosage and combination]

M Fliri1

  • 1I. Med. Klinik, Klinikum Augsburg.

MMW Fortschritte Der Medizin
|January 21, 2003
PubMed

Insights

Current chronic heart failure treatments include ACE inhibitors, beta blockers, and aldosterone antagonists, which improve prognosis. Other drugs lower morbidity but require further study for long-term benefits.

Area of Science:

  • Cardiology
  • Pharmacology

Background:

  • Chronic heart failure (CHF) management follows European Society of Cardiology guidelines, tailored to NYHA stages.
  • Current pharmacotherapy includes ACE inhibitors, beta blockers, AT1 receptor antagonists, diuretics (with aldosterone antagonists), and digitalis.

Purpose of the Study:

  • To review current medical treatments for chronic heart failure.
  • To evaluate the prognostic impact of established CHF therapies.
  • To explore novel therapeutic strategies targeting neurohumoral and maladaptive processes in CHF.

Main Methods:

  • Review of current treatment guidelines and pharmacological agents for CHF.
  • Analysis of evidence supporting the prognostic impact of different drug classes.
  • Identification of emerging therapeutic targets and concepts in CHF management.

Main Results:

  • ACE inhibitors, beta blockers, and aldosterone antagonists demonstrate a positive impact on CHF prognosis.
  • Diuretics and digitalis primarily offer morbidity reduction, with less confirmed prognostic benefit.
  • Novel strategies aim to inhibit maladaptive pathways or promote protective mechanisms, pending randomized study results.

Conclusions:

  • Established therapies like ACE inhibitors, beta blockers, and aldosterone antagonists are crucial for improving CHF prognosis.
  • Ongoing research is essential to validate newer therapeutic approaches targeting neurohumoral axes and local processes in heart failure.

Related Concept Videos

Heart Failure Drugs: β-Blockers01:22

Heart Failure Drugs: β-Blockers

β-adrenergic antagonists, commonly known as β-blockers, block the effects of sympathetic neurotransmitters such as noradrenaline (NA) and adrenaline (ADR). They have several beneficial effects in heart failure treatment. They reduce heart rate, the force of contraction, and cardiac muscle relaxation. They also slow the atrial-ventricular conduction rate and raise the threshold for arrhythmias. The concentration of β-blockers determines their effects on bronchodilation, vasodilation, and...
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System01:26

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System

The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
Heart Failure V: Medical Management01:30

Heart Failure V: Medical Management

Medical Management of Acute Decompensated Heart Failure (ADHF)The primary goals of therapy for patients hospitalized with acute decompensated heart failure (ADHF) include:Relieving symptomsOptimizing volume statusSupporting oxygenation and ventilationMaintaining cardiac output (CO) and end-organ perfusionIdentifying and addressing the cause of ADHFPreventing complicationsProviding patient education on factors precipitating HF exacerbationPlanning for dischargeOngoing monitoring and assessment...
Antihypertensive Drugs: Types of β-Blockers01:28

Antihypertensive Drugs: Types of β-Blockers

β receptors are classified into three subclasses: β1, β2, and β3. β1 receptors are primarily located in the heart and kidneys. When they get activated, they increase heart rate, contractility, and renin release. This process enhances blood pressure and aids in stress management. In contrast, β2 receptors are situated mainly in the lungs, blood vessels, and skeletal muscles. Upon activation, they trigger smooth muscle relaxation, causing bronchodilation and vasodilation. This widens airways and...
Antihypertensive Drugs: Action of β1 Blockers01:17

Antihypertensive Drugs: Action of β1 Blockers

β1-receptors are primarily located in the heart and kidneys. In cardiac myocytes, these receptors interact with neurotransmitters released by the sympathetic nervous system during heightened activity or danger. As a result, β1-receptors get activated, initiating a series of biochemical processes. Excessive activation of beta receptors due to chronic stress can abnormally increase heart rate and contractility, resulting in high blood pressure or hypertension. To counteract this, β1-blockers...
Adrenergic Antagonists: Pharmacological Actions of β-Receptor Blockers01:27

Adrenergic Antagonists: Pharmacological Actions of β-Receptor Blockers

β-receptor blockers significantly impact the cardiovascular system by counteracting catecholamine-induced sympathetic responses. These medications decrease heart rate, contractility, and cardiac output, potentially leading to cardiac depression, life-threatening bradycardia, and death. Therapeutically, β-blockers function as mild antihypertensives and are utilized in treating angina pectoris and cardiac arrhythmias. However, nonselective β-blockers inhibit β2-receptors in bronchial smooth...